Merck beats Q1 sales estimates as Keytruda demand drives earnings guidance raise
Full-year earnings guidance lifted; new products cited alongside Keytruda as growth contributors
Briefing
- •Merck reported higher first-quarter sales, beating consensus estimates, with Keytruda remaining the primary growth driver.
- •The company raised its full-year earnings guidance following the Q1 beat.
- •New products contributed alongside Keytruda to the quarterly outperformance.
- •Merck narrowed its full-year outlook, signalling tighter confidence in the range of expected results.
Analysis
- →Keytruda's continued dominance as Merck's primary growth driver, combined with a guidance raise and range-narrowing, reinforces the oncology biologics thesis heading into the post-LOE cliff debate. The guidance tightening signals management confidence in near-term demand visibility, which reduces the probability of a downside revision before the patent expiry overhang becomes operationally material. Competing PD-1/L1 developers and biosimilar entrants face a higher bar to displace Keytruda in combination regimens, where switching costs are elevated.
- →A Q1 beat with guidance raised across multiple large-cap names, including Caterpillar, Samsung, UBS, and now Merck, is building a pattern of broad earnings resilience that compresses the probability of an imminent earnings-led recession trade. For healthcare specifically, Merck's outperformance isolates the sector from macro demand risk, making MRK a relative safe-haven beneficiary if tariff or rates uncertainty re-emerges and rotates capital out of cyclicals.
Historical Context
- 2021-2023
Keytruda became the world's best-selling drug, with Merck repeatedly raising guidance on oncology demand. Each guidance raise extended investor tolerance for the eventual 2028 LOE cliff, as durable sales growth pushed the effective earnings impact further out, compressing the discount rate applied to post-patent cash flows.
- 2018
Bristol-Myers Squibb's Opdivo failed a high-profile lung cancer trial while Keytruda succeeded, permanently shifting PD-1 market share to Merck. That episode demonstrated how combination regimen entrenchment creates durable competitive moats that make biosimilar displacement structurally harder than in antibody or small-molecule markets.